Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Metastatic Urothelial Carcinoma
• Age: Between 18 Year(s) - 100 Year(s)
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1. Patients with histologically confirmed urothelial cancer of the renal pelvis, ureter, bladder or urethra. Both transitional cell and mixed transitional cell / non-transitional cell are allowed but transitional cell histology must be predominant. 2. Cohort 1: Have had progression or recurrence of urothelial cancer following receipt of platinum-containing regimen (cisplatin or carboplatin). 3. Have had progression or recurrence of urothelial cancer following receipt of an anti-PD-1 / anti-PD-LI therapy. OR Have had progression or recurrence of urothelial cancer after a first-line therapy for metastatic disease.
  

You may not be eligible for this study if the following are true:

• 1. Has a diagnosis of immunodeficiency. 2. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study Day 1 or who has not recovered (i.e., < Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. 3. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered fro adverse events due to a previously administered agent.